BR112013027229A2 - composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas - Google Patents

composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas

Info

Publication number
BR112013027229A2
BR112013027229A2 BR112013027229A BR112013027229A BR112013027229A2 BR 112013027229 A2 BR112013027229 A2 BR 112013027229A2 BR 112013027229 A BR112013027229 A BR 112013027229A BR 112013027229 A BR112013027229 A BR 112013027229A BR 112013027229 A2 BR112013027229 A2 BR 112013027229A2
Authority
BR
Brazil
Prior art keywords
clostridium difficile
mutant
methods
toxin
difficile toxin
Prior art date
Application number
BR112013027229A
Other languages
English (en)
Other versions
BR112013027229B1 (pt
Inventor
Annaliesa Sybil Anderson
Justin Keith Moran
Kathrin Ute Jansen
Maninder K Sidhu
Mark E Ruppen
Michael James Flint
Narender K Kalyan
Robert G K Donald
Terri L Mininni
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Priority to BR122019017005-3A priority Critical patent/BR122019017005B1/pt
Publication of BR112013027229A2 publication Critical patent/BR112013027229A2/pt
Publication of BR112013027229B1 publication Critical patent/BR112013027229B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas em um aspecto, a invenção refere-se a uma composição imunogênica que inclui uma toxina a de clostridium difficile mutante e/ou uma toxina b de clostridium difficile mutante. cada toxina mutante inclui um domínio de glucosiltransferase que possui pelo menos uma mutação e um domínio de cisteína protease que possui pelo menos uma mutação, em relação à toxina de c. difficile do tipo selvagem correspondente. as toxinas mutantes podem incluir ainda pelo menos um aminoácido que é quimicamente reticulado. em outro aspecto, a invenção refere-se a anticorpos ou fragmentos de ligação dos mesmos que se ligam às ditas composições imunogênicas. em aspectos adicionais, a invenção refere-se a sequências de nucleotídeos isoladas que codificam qualquer um do que foi descrito anteriormente e métodos de uso de qualquer uma das composições anteriores.
BR112013027229-5A 2011-04-22 2012-04-20 polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante BR112013027229B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019017005-3A BR122019017005B1 (pt) 2011-04-22 2012-04-20 Composições que se relacionam a uma toxina de clostridium difficile mutante

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161478474P 2011-04-22 2011-04-22
US61/478,474 2011-04-22
US201161478899P 2011-04-25 2011-04-25
US61/478,899 2011-04-25
PCT/IB2012/051999 WO2012143902A1 (en) 2011-04-22 2012-04-20 Compositions relating to a mutant clostridium difficile toxin and methods thereof

Publications (2)

Publication Number Publication Date
BR112013027229A2 true BR112013027229A2 (pt) 2016-11-29
BR112013027229B1 BR112013027229B1 (pt) 2020-10-27

Family

ID=46085103

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013027229-5A BR112013027229B1 (pt) 2011-04-22 2012-04-20 polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
BR122019017005-3A BR122019017005B1 (pt) 2011-04-22 2012-04-20 Composições que se relacionam a uma toxina de clostridium difficile mutante

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019017005-3A BR122019017005B1 (pt) 2011-04-22 2012-04-20 Composições que se relacionam a uma toxina de clostridium difficile mutante

Country Status (29)

Country Link
US (13) US8481692B2 (pt)
EP (4) EP3549949B1 (pt)
JP (8) JP5917682B2 (pt)
KR (1) KR101667837B1 (pt)
CN (3) CN111647059B (pt)
AR (1) AR086199A1 (pt)
AU (6) AU2012245904B2 (pt)
BR (2) BR112013027229B1 (pt)
CA (1) CA2832712C (pt)
CO (1) CO6801643A2 (pt)
DK (2) DK3549949T3 (pt)
ES (3) ES2742823T3 (pt)
FI (1) FI3549949T3 (pt)
HR (2) HRP20240042T1 (pt)
HU (1) HUE047085T2 (pt)
IL (8) IL270779B1 (pt)
MX (1) MX347521B (pt)
MY (2) MY168205A (pt)
NZ (1) NZ616035A (pt)
PE (2) PE20181334A1 (pt)
PL (3) PL3549949T3 (pt)
PT (2) PT2699587T (pt)
RU (2) RU2592686C2 (pt)
SA (3) SA115360698B1 (pt)
SG (3) SG194132A1 (pt)
SI (3) SI2699587T1 (pt)
TW (6) TWI815599B (pt)
WO (1) WO2012143902A1 (pt)
ZA (1) ZA201307818B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
RU2477753C2 (ru) * 2008-12-09 2013-03-20 Коули Фармасьютикал Груп, Инк. Иммуностимулирующие олигонуклеотиды
JP6121421B2 (ja) 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
SI2699587T1 (sl) 2011-04-22 2019-08-30 Wyeth Llc Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka
RU2014127714A (ru) * 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CN109369808B (zh) 2012-08-24 2023-11-07 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
US20140081659A1 (en) 2012-09-17 2014-03-20 Depuy Orthopaedics, Inc. Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
LT2916866T (lt) * 2012-11-06 2018-07-25 Bayer Pharma Aktiengesellschaft Bispecifinių t ląstelių aktyvatorių (bites) kompozicija
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
WO2014176276A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
US9730994B2 (en) 2013-06-14 2017-08-15 Sanofi Pasteur, Inc. Compositions and methods for immunizing against C. difficile
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
HUE038212T2 (hu) * 2014-07-25 2018-10-29 Biosynth Srl Többszörös beépített epitópokat kifejezõ molekuláris konstrukt bázikus egységeket tartalmazó glikokonjugátum vakcinák enteropatogén baktériumok által okozott fertõzések elleni szélesspektrumú vakcina elõállításához
WO2016130923A1 (en) * 2015-02-13 2016-08-18 Quanterix Corporation Immunoassays for diffrential detection of clostridium difficile
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
US20190211377A1 (en) * 2016-12-22 2019-07-11 Roche Molecular Systems, Inc. Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile
KR102625114B1 (ko) * 2017-09-28 2024-01-12 화이자 인코포레이티드 클로스트리디움 디피실레에 대항한 면역 반응을 도출하기 위한 조성물 및 방법
WO2020201985A1 (en) 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
US20220313809A1 (en) * 2019-05-10 2022-10-06 The Board Of Regents Of The University Of Oklahoma Clostridioides difficile tcdb variants, vaccines and methods of use
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
CA3177003A1 (en) * 2020-05-06 2021-11-11 Vern L. Schramm Agents to prevent tissue damage from clostridium difficile infections by inhibition of the gut-damaging bacterial toxins tcda and tcdb
CN111755068B (zh) * 2020-06-19 2021-02-19 深圳吉因加医学检验实验室 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2023175454A1 (en) 2022-03-14 2023-09-21 Pfizer Inc. Methods for producing an adjuvant
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
ES2113428T3 (es) 1991-04-22 1998-05-01 Massachusetts Health Res Proceso de tamizado de muestras de plasma para determinar titulos de anticuerpos efectivos contra los virus respiratorios.
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
CA2158651C (en) 1993-03-29 2009-09-01 David S. Roberts Multicomponent clostridial vaccines using saponin adjuvants
EP0779819A1 (en) 1994-09-06 1997-06-25 Galagen Inc. Therapeutic treatment of clostridium difficile associated diseases
CZ296806B6 (cs) 1994-10-24 2006-06-14 Allergan, Inc. Rozpustný fúzní protein a zpusob výroby rozpustného rekombinantního botulinového toxinu
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
CN1195993A (zh) 1995-07-07 1998-10-14 奥拉瓦克斯有限公司 抗胃肠疾病的鼻内接种
NZ312502A (en) 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants
DE69635496T2 (de) * 1995-09-15 2006-07-27 Gerding, Dale N., Chicago Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
ES2237801T3 (es) 1996-07-12 2005-08-01 First Opinion Corporation Sistema informatizado de asesoramiento de diagnostico y tratamiento medico incluyendo el acceso de red.
KR100382224B1 (ko) 1996-09-30 2003-04-26 엠브렉스, 인코포레이티드 백신 컨쥬게이트를 이용한 능동면역 생성방법
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
JP5087758B2 (ja) 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
CA2307331C (en) 1997-10-20 2017-03-21 Oravax, Inc. Passive immunization against clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
AU781027B2 (en) * 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
WO2000061762A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
KR20030019366A (ko) * 2000-05-04 2003-03-06 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 세균 감염의 치료 및 예방을 위한 화합물 및 방법
US20050053575A1 (en) * 2001-06-20 2005-03-10 Ramot At Tel Aviv University Ltd Antigenic product displaying multiple copies of an epitope of a deposit-forming polypeptide involved in plaque-forming diseases and methods of using same
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7750204B2 (en) 2002-06-05 2010-07-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibody
US7226597B2 (en) * 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
ES2295836T3 (es) * 2003-03-13 2008-04-16 Glaxosmithkline Biologicals S.A. Procedimiento de purificacion de citolisina bacteriana.
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
JP5602336B2 (ja) 2004-01-16 2014-10-08 フェネックス インコーポレイテッド シュードモナス・フルオレッセンスにおける哺乳動物タンパク質の発現
NZ530709A (en) 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
NZ580828A (en) * 2004-02-06 2011-09-30 Univ Massachusetts Antibodies against clostridium difficile toxin B and uses thereof
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
CA2592015A1 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1987361A4 (en) * 2006-01-30 2009-03-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
HUE027091T2 (en) * 2006-03-30 2016-08-29 Zoetis Services Llc Procedures and preparations for vaccination of poultry
US8852600B2 (en) * 2006-06-08 2014-10-07 The Rockefeller University Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
WO2008024769A2 (en) 2006-08-21 2008-02-28 Raven Biotechnologies, Inc. Intensified perfusion production method
US7775167B2 (en) 2006-08-22 2010-08-17 Monsanto Technology Llc Custom planter and method of custom planting
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
US9023352B2 (en) * 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
WO2008108082A1 (ja) * 2007-03-02 2008-09-12 Panasonic Corporation 音声復号装置および音声復号方法
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
CA2699435A1 (en) * 2007-09-14 2009-03-19 Sanofi Pasteur Biologics Co. Pharmaceutical compositions containing clostridium difficile toxoids a and b
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
EP2288719A4 (en) 2008-05-15 2012-01-11 Univ Tufts DIFFICULT CLOSTRIDIUM DIAGNOSTIC METHODS AND METHODS AND VECTORS FOR EXPRESSION OF RECOMBINANT TOXINS
US9421251B2 (en) 2008-06-25 2016-08-23 Novartis Ag Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
EP2318515A4 (en) 2008-08-06 2012-11-14 Emergent Product Dev Uk Ltd DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE
EP2329029B1 (en) 2008-09-24 2016-06-08 Sanofi Pasteur Biologics, LLC Methods and compositions for increasing toxin production
EP2346523A4 (en) 2008-10-01 2014-12-31 Us Health MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM
US10369204B2 (en) * 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
WO2010063693A1 (en) 2008-12-03 2010-06-10 Boehringer Ingelheim Vetmedica Gmbh Process for production of vaccines
RU2477753C2 (ru) 2008-12-09 2013-03-20 Коули Фармасьютикал Груп, Инк. Иммуностимулирующие олигонуклеотиды
GB0901001D0 (en) * 2009-01-22 2009-03-04 Univ Nottingham Methods
US8709428B2 (en) * 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
WO2011031568A2 (en) 2009-08-27 2011-03-17 Synaptic Research, Llc A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
CA2782406A1 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101870978A (zh) * 2010-03-23 2010-10-27 王世霞 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗
CA2793978C (en) 2010-03-30 2021-08-03 Pfenex Inc. High level expression of recombinant toxin proteins
US8765399B2 (en) 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
JP6121421B2 (ja) 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
US9285372B2 (en) * 2010-11-12 2016-03-15 Reflexion Pharmaceuticals, Inc. Methods and compositions for identifying D-peptidic compounds that specifically bind target proteins
SI2699587T1 (sl) 2011-04-22 2019-08-30 Wyeth Llc Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka
SI2714910T1 (en) 2011-05-27 2018-04-30 Glaxosmithkline Biologicals Sa An immunogenic composition
US9770500B2 (en) * 2011-05-31 2017-09-26 The Board Of Regents Of The University Of Texas System S-nitrosylation of glucosylating toxins and uses therefor
RU2014127714A (ru) * 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
JP2015529677A (ja) 2012-09-19 2015-10-08 ノバルティス アーゲー ワクチンとしてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅポリペプチド
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN109776676A (zh) 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
PT3513806T (pt) 2012-12-05 2023-03-02 Glaxosmithkline Biologicals Sa Composição imunogénica
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
JP2016516721A (ja) 2013-03-15 2016-06-09 サノフィ パストゥール インコーポレイテッド トキソイド、組成物および関連方法
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
EP2981611A4 (en) 2013-04-02 2016-11-16 Stc Unm ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH
US9730994B2 (en) 2013-06-14 2017-08-15 Sanofi Pasteur, Inc. Compositions and methods for immunizing against C. difficile
US20160250283A1 (en) 2013-10-23 2016-09-01 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
RU2761633C2 (ru) 2015-11-17 2021-12-13 Пфайзер Инк. Среды и способы ферментации для производства полисахаридов в бактериальной клеточной культуре
US10813988B2 (en) 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
WO2018170238A2 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
CA3016351A1 (en) 2017-09-05 2019-03-05 Mcmaster University Aptamers for clostridium difficile detection
KR102625114B1 (ko) 2017-09-28 2024-01-12 화이자 인코포레이티드 클로스트리디움 디피실레에 대항한 면역 반응을 도출하기 위한 조성물 및 방법
JP6704173B2 (ja) 2019-09-26 2020-06-03 パナソニックＩｐマネジメント株式会社 開閉器及び分電盤

Also Published As

Publication number Publication date
RU2592686C2 (ru) 2016-07-27
TW201806967A (zh) 2018-03-01
SI3549949T1 (sl) 2024-02-29
TWI686402B (zh) 2020-03-01
EP2699587A1 (en) 2014-02-26
RU2015154443A3 (pt) 2019-05-22
USRE48863E1 (en) 2021-12-28
US20130330371A1 (en) 2013-12-12
IL265510B (en) 2021-05-31
EP3505531A1 (en) 2019-07-03
SI2699587T1 (sl) 2019-08-30
TWI815599B (zh) 2023-09-11
CO6801643A2 (es) 2013-11-29
USRE46518E1 (en) 2017-08-22
TW201302780A (zh) 2013-01-16
AU2018201296A1 (en) 2018-03-15
JP2022126822A (ja) 2022-08-30
IL255345B (en) 2021-05-31
ES2968629T3 (es) 2024-05-13
ZA201307818B (en) 2014-06-25
EP3505531B1 (en) 2023-11-15
IL273231A (en) 2020-04-30
CA2832712A1 (en) 2012-10-26
IL273231B (en) 2021-08-31
AU2020230248B2 (en) 2022-12-01
JP6321239B2 (ja) 2018-05-09
EP3549949A1 (en) 2019-10-09
IL245047A0 (en) 2016-05-31
IL254440A0 (en) 2017-11-30
IL270779B1 (en) 2024-05-01
US20150307563A1 (en) 2015-10-29
NZ616035A (en) 2016-03-31
IL255345A0 (en) 2017-12-31
AU2019246878B2 (en) 2020-09-10
EP3549949B1 (en) 2023-11-29
US20190202873A1 (en) 2019-07-04
US9187536B1 (en) 2015-11-17
KR20130140206A (ko) 2013-12-23
IL270779A (en) 2020-01-30
PE20181334A1 (es) 2018-08-21
CN103619871A (zh) 2014-03-05
DK3549949T3 (da) 2023-12-18
TWI671313B (zh) 2019-09-11
JP2018052938A (ja) 2018-04-05
HRP20240042T1 (hr) 2024-03-29
IL228944A (en) 2017-11-30
JP5917682B2 (ja) 2016-05-18
AU2017261465A1 (en) 2017-11-30
US20230391835A1 (en) 2023-12-07
US10597428B2 (en) 2020-03-24
TW201932481A (zh) 2019-08-16
JP2018135345A (ja) 2018-08-30
TWI650329B (zh) 2019-02-11
EP2699587B1 (en) 2019-07-03
BR112013027229B1 (pt) 2020-10-27
HUE047085T2 (hu) 2020-04-28
PL3505531T3 (pl) 2024-03-11
IL265510A (en) 2019-05-30
WO2012143902A1 (en) 2012-10-26
CN103619871B (zh) 2016-12-14
JP2021130692A (ja) 2021-09-09
USRE46376E1 (en) 2017-04-25
JP2014514318A (ja) 2014-06-19
AU2016202903B2 (en) 2017-11-30
AR086199A1 (es) 2013-11-27
AU2019246878A1 (en) 2019-10-31
US10774117B2 (en) 2020-09-15
PL2699587T3 (pl) 2019-12-31
CN107022532A (zh) 2017-08-08
CN111647059A (zh) 2020-09-11
US20120269841A1 (en) 2012-10-25
AU2012245904B2 (en) 2016-04-21
TW202320843A (zh) 2023-06-01
HRP20231631T1 (hr) 2024-03-15
US8557548B2 (en) 2013-10-15
US9745354B2 (en) 2017-08-29
RU2754446C2 (ru) 2021-09-02
SG10201602668VA (en) 2016-05-30
US8900597B2 (en) 2014-12-02
SA115360697B1 (ar) 2016-04-05
SA115360698B1 (ar) 2016-04-27
EP4365196A2 (en) 2024-05-08
RU2013145170A (ru) 2015-06-27
IL254418A0 (en) 2017-11-30
CA2832712C (en) 2018-08-28
US20200095290A1 (en) 2020-03-26
BR122019017005B1 (pt) 2022-03-29
TWI701257B (zh) 2020-08-11
MX2013012344A (es) 2013-11-20
US11535652B2 (en) 2022-12-27
US20170313749A1 (en) 2017-11-02
TW202041525A (zh) 2020-11-16
PT2699587T (pt) 2019-09-05
CN107022532B (zh) 2021-05-04
JP2017125030A (ja) 2017-07-20
SI3505531T1 (sl) 2024-02-29
IL228944A0 (en) 2013-12-31
AU2020230248A1 (en) 2020-10-01
MY168205A (en) 2018-10-15
AU2017261465B2 (en) 2018-10-04
ES2742823T3 (es) 2020-02-17
MX347521B (es) 2017-04-27
FI3549949T3 (fi) 2024-01-30
ES2969952T3 (es) 2024-05-23
JP6892425B2 (ja) 2021-06-23
TWI804717B (zh) 2023-06-11
JP6097853B2 (ja) 2017-03-15
DK2699587T3 (da) 2019-08-05
USRE48862E1 (en) 2021-12-28
SG10201911993UA (en) 2020-02-27
JP6735784B2 (ja) 2020-08-05
AU2012245904A1 (en) 2013-10-17
US20130244307A1 (en) 2013-09-19
US20150125927A1 (en) 2015-05-07
PT3549949T (pt) 2024-02-02
IL254440B (en) 2019-12-31
PL3549949T3 (pl) 2024-04-08
IL254418B (en) 2019-12-31
AU2016202903A1 (en) 2016-05-26
CN111647059B (zh) 2023-11-28
KR101667837B1 (ko) 2016-10-20
JP7097478B2 (ja) 2022-07-07
TW201932480A (zh) 2019-08-16
SG194132A1 (en) 2013-11-29
MY182429A (en) 2021-01-25
US8481692B2 (en) 2013-07-09
JP2016117745A (ja) 2016-06-30
JP2019052149A (ja) 2019-04-04
PE20141029A1 (es) 2014-09-04
SA112330472B1 (ar) 2015-11-02
RU2015154443A (ru) 2019-01-17

Similar Documents

Publication Publication Date Title
BR112013027229A2 (pt) composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas
BR112015008844A8 (pt) composições e métodos relacionados a uma toxina de clostridium difficile mutante
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
BR112014008529A2 (pt) il-6 humanizado e receptor de il-6
BR112014017165A8 (pt) polipeptídeos de fator quimérico viii e seus usos
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
BRPI0818765A8 (pt) Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo
TR201903707T4 (tr) Aşırı yükleme ve elüsyon kromatografisi.
BR112013003825A2 (pt) conjugados, partículas, composições e métodos relacionados
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112016014405A2 (pt) cepa mutante atenuada de salmonela
BR112012004697A2 (pt) purificação melhorada de proteína através de uma eluição da proteína a modificada.
BR112018015754A2 (pt) anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
BR112015013004A2 (pt) molécula de ácido nucleico isolada, composição, vacina, métodos de tratamento de um indivíduo e de prevenção de um tumor, proteína, e, peptídeo
BRPI0702163A (pt) composições de toner e métodos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/04/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: WYETH LLC (US)